Flag of the European Union EU Clinical Trials Register Help

Clinical trials for lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,346 result(s) found for: lymphoma. Displaying page 42 of 68.
    EudraCT Number: 2012-004053-88 Sponsor Protocol Number: EuroNet-PHL-C2 Start Date*: 2015-07-01
    Sponsor Name:Justus-Liebig-University Giessen
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: Hodgkin lymphoma in children and adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) NL (Completed) DK (Prematurely Ended) FR (Ongoing) PL (Prematurely Ended) FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004848-36 Sponsor Protocol Number: BAY80-6946/17119 Start Date*: 2015-05-05
    Sponsor Name:Bayer AG
    Full Title: An open-label, single-arm Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to evaluate efficacy and safety of treatment with single agent copanlisib and ...
    Medical condition: patients with relapsed or refractory diffuse large B cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002739-14 Sponsor Protocol Number: ACT14596 Start Date*: 2016-12-07
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients with Relapsed or Refractory T-acute Lymphoblastic Leukemia ...
    Medical condition: Haematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042987 T-cell type acute leukaemia PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036543 Precursor T-lymphoblastic lymphoma/leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005811-16 Sponsor Protocol Number: OMB110913 Start Date*: 2008-12-22
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GR (Completed) IT (Completed) ES (Completed) GB (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-002848-32 Sponsor Protocol Number: M-2017-322 Start Date*: 2018-05-15
    Sponsor Name:Miltenyi Biomedicine GmbH
    Full Title: A phase I/II safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies.
    Medical condition: Pediatric and adult patients with relapsed/refractory (r/r) CD19-expressing B cell acute lymphoblastic leukemia (ALL) and Non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008977 Chronic lymphocytic leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008978 Chronic lymphocytic leukemia refractory LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004288-11 Sponsor Protocol Number: ADCT-402-201 Start Date*: 2018-08-10
    Sponsor Name:ADC Therapeutics SA
    Full Title: A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Medical condition: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004977-12 Sponsor Protocol Number: MO19872 Start Date*: 2006-06-22
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy.
    Medical condition: Follicular non Hodgkin's Lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) SE (Completed) SK (Completed) IT (Completed) GR (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002100-83 Sponsor Protocol Number: BH29812 Start Date*: 2016-05-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RITUXIMAB IN C...
    Medical condition: Relapsed or refractory (R/R) follicular lymphoma or diffuse large B-cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002620-32 Sponsor Protocol Number: CCR3862 Start Date*: 2013-04-02
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in second-line t...
    Medical condition: Relapsed or refractory diffuse large B-cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-001641-33 Sponsor Protocol Number: PETAL-Studie Start Date*: 2007-07-25
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas)
    Medical condition: Aggressive non-Hodgkin's lymphomas (first line therapy)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003703-62 Sponsor Protocol Number: FIL_DEVEC Start Date*: 2017-04-27
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell lymphomas.
    Medical condition: B-Cell lymphomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003277-22 Sponsor Protocol Number: FIL_FOLL19 Start Date*: 2021-10-04
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymphoma. A randomized, open label, phase III study by Fondazi...
    Medical condition: High tumor burden Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004864 10080213 In situ follicular lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003668-11 Sponsor Protocol Number: E7080-G000-604 Start Date*: 2018-07-30
    Sponsor Name:Eisai Ltd.
    Full Title: An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored...
    Medical condition: solid tumors or lymphomas, as defined in parent protocol
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025315 Lymphoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-005923-42 Sponsor Protocol Number: TACL2008-002/ITCC033 Start Date*: 2013-04-09
    Sponsor Name:TACL
    Full Title: A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC
    Medical condition: relapsed T-ALL, T-NHL
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024338 Leukemia lymphoblastic acute LLT
    14.1 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) AT (Prematurely Ended) GB (Completed) IT (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002950-38 Sponsor Protocol Number: MK-3475-051 Start Date*: 2014-11-10
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
    Medical condition: Treatment of advanced melanoma or advanced, relapsed or refractory PD-L1 positive malignant solid tumor or lymphoma in children from 6 months to less than 18 years old.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003206-41 Sponsor Protocol Number: LOXO-BTK-20030(J2N-OX-JZNU) Start Date*: 2022-08-03
    Sponsor Name:Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
    Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) CZ (Trial now transitioned) PT (Prematurely Ended) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005324-10 Sponsor Protocol Number: CT-P10_3.4 Start Date*: 2015-08-20
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma
    Medical condition: Low Tumour Burden Follicular Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001039-29 Sponsor Protocol Number: GO40515 Start Date*: 2019-02-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR ...
    Medical condition: B-Cell Non-Hodgkin Lymphoma (B-cell NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005197-10 Sponsor Protocol Number: VT3996-202 Start Date*: 2021-10-01
    Sponsor Name:Viracta Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
    Medical condition: Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071441 Epstein-Barr virus associated lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004151-39 Sponsor Protocol Number: 0761-007 Start Date*: 2012-03-16
    Sponsor Name:Kyowa Hakko Kirin Pharma, Inc.
    Full Title: Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) in Subjects with Previously Treated Peripheral T-cell Lymphoma (PTCL)
    Medical condition: Treatment of patients with relapsed or refractory PTCL
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034626 Peripheral T-cell lymphoma unspecified refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 12:33:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA